Document Detail


Anticoagulants in acute coronary syndromes.
MedLine Citation:
PMID:  10505536     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Antithrombotic and antiplatelet agents, particularly unfractionated heparin and aspirin, are longstanding therapeutic mainstays for acute coronary syndromes such as unstable angina and non-Q-wave myocardial infarction (MI). Early studies demonstrated that aspirin reduces the risk of mortality or nonfatal MI by 50-70% in patients presenting with unstable angina or non-Q-wave MI. Added to aspirin, heparin regimens further diminish the incidence of these myocardial ischemic events in the acute setting. Three major clinical studies demonstrated that such enhanced risk reductions can be achieved without significant increases in bleeding complications. The low-molecular-weight (LMW) heparin, dalteparin, proved superior to placebo but not unfractionated heparin in diminishing the incidence of (1) death or MI; (2) death, MI, or recurrence of angina; or (3) frequency of revascularization procedures. On the other hand, another LMW heparin, enoxaparin, did reduce these events at 14 and 30 days, as well as 1 year after treatment. The principal biophysical limitation of heparins, however, is that they cannot inactivate clot-bound thrombin, which probably contributes to morbidity and mortality in acute coronary syndromes. The natural leech-derived polypeptide hirudin and its derivatives (e.g., lepirudin) inactivate both fibrin-bound and free thrombin. Lepirudin has been approved in certain countries for the treatment of heparin-induced thrombocytopenia and is now being evaluated in the clinical management of acute myocardial ischemic syndromes. The well-documented pathophysiologic foundation for acute coronary syndromes is partial or intermittent thrombotic occlusion of a coronary artery as the result of atherosclerosis. Although a stable atherosclerotic plaque may not be clinically problematic, plaque rupture, which occurs under a variety of stimuli, touches off a cascade of enzymatic and cellular responses that frequently culminate in thrombotic occlusion. In the coronary circulation, such an occlusion may cause transmural MI, unstable angina, or non-Q-wave MI. Because the pathogenetic mechanisms of atherosclerosis with thrombotic complications have been elucidated, this knowledge can be translated into a rational clinical approach using antithrombotic therapies.
Authors:
A G Turpie
Related Documents :
12783606 - Evolving role of bivalirudin in percutaneous coronary interventions; impact of the repl...
9973856 - Thrombolysis in the management of acute myocardial infarction. current status and futur...
11253856 - Clinical use of new antithrombotic therapies for medical management of acute coronary s...
15215806 - The warfarin/aspirin study in heart failure (wash): a randomized trial comparing antith...
19089936 - Percutaneous coronary intervention in anticoagulated patients via radial artery access.
24577966 - Translating koch's postulates to identify matrix metalloproteinase roles in postmyocard...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  84     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1999 Sep 
Date Detail:
Created Date:  1999-10-07     Completed Date:  1999-10-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2M-6M     Citation Subset:  AIM; IM    
Affiliation:
McMaster University, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Angina, Unstable / drug therapy
Anticoagulants / therapeutic use*
Aspirin / therapeutic use*
Clinical Trials as Topic
Coronary Disease / drug therapy*
Dalteparin / therapeutic use
Enoxaparin / therapeutic use
Fibrinolytic Agents / therapeutic use
Heparin, Low-Molecular-Weight / therapeutic use*
Hirudin Therapy*
Hirudins / analogs & derivatives
Humans
Myocardial Infarction / drug therapy
Recombinant Proteins / therapeutic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Dalteparin; 0/Enoxaparin; 0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 0/Hirudins; 0/Recombinant Proteins; 0/lepirudin; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of circumferential plasma-spray porous coating on the rate of femoral osteolysis after total ...
Next Document:  The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unsta...